US6472147B1
(en)
*
|
1999-05-25 |
2002-10-29 |
The Scripps Research Institute |
Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
|
WO2001023619A1
(en)
*
|
1999-09-29 |
2001-04-05 |
Xenoport, Inc. |
Compounds displayed on replicable genetic packages and methods of using same
|
US7037706B1
(en)
|
1999-09-29 |
2006-05-02 |
Xenoport, Inc. |
Compounds displayed on replicable genetic packages and methods of using same
|
EP2295580A1
(en)
*
|
2000-04-17 |
2011-03-16 |
Dyax Corp. |
Methods of constructing display libraries of genetic packages for members of a diverse family of peptides
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
AU2002249854B2
(en)
|
2000-12-18 |
2007-09-20 |
Dyax Corp. |
Focused libraries of genetic packages
|
US7229757B2
(en)
|
2001-03-21 |
2007-06-12 |
Xenoport, Inc. |
Compounds displayed on icosahedral phage and methods of using same
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
US7202045B2
(en)
*
|
2001-09-19 |
2007-04-10 |
Regents Of The University Of Michigan |
Detection and treatment of cancers of the lung
|
US7175983B2
(en)
*
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
AU2003253193B2
(en)
*
|
2002-07-30 |
2009-07-02 |
Morphosys Ag |
Novel tricistronic vectors and uses therefor
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
ATE432290T1
(de)
|
2002-11-09 |
2009-06-15 |
Immunocore Ltd |
T ZELL REZEPTOR ßDISPLAYß
|
EP2290107A1
(en)
|
2003-01-07 |
2011-03-02 |
Dyax Corporation |
Kunitz domain library
|
SI2511297T1
(sl)
|
2004-02-06 |
2015-07-31 |
Morphosys Ag |
Proti -CD38 humana protitelesa in njihova uporaba
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
KR20140066259A
(ko)
|
2004-02-06 |
2014-05-30 |
모르포시스 아게 |
항-cd38 인간 항체 및 그의 용도
|
EP1855723B1
(en)
|
2005-03-08 |
2013-05-22 |
Ramot at Tel-Aviv University Ltd. |
Targeted drug-carrying bacteriophages
|
PT1888643E
(pt)
|
2005-05-18 |
2015-01-14 |
Morphosys Ag |
Anticorpos anti-fec-gm e as respectivas utilizações
|
US8114964B2
(en)
|
2005-05-19 |
2012-02-14 |
Centocor, Inc. |
Anti-MCP-1 antibodies, compositions, methods and uses
|
TW200745162A
(en)
|
2005-05-24 |
2007-12-16 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
SI2860192T1
(en)
|
2005-10-12 |
2018-04-30 |
Morphosys Ag |
Generating and profiling fully human HuCAL GOLD-specific therapeutic antibodies specific to human CD38
|
EP1945767B1
(de)
|
2005-11-09 |
2010-04-07 |
MorphoSys AG |
Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
NZ569359A
(en)
*
|
2005-12-20 |
2011-11-25 |
Morphosys Ag |
Novel collection of HCDR3 regions and uses therefor
|
EP2004693B1
(en)
|
2006-03-30 |
2012-06-06 |
Novartis AG |
Compositions and methods of use for antibodies of c-met
|
JP2009535063A
(ja)
|
2006-05-04 |
2009-10-01 |
アブマクシス・インコーポレイテツド |
異種間及び複数種提示系
|
NZ574140A
(en)
|
2006-07-05 |
2012-02-24 |
Catalyst Biosciences Inc |
Protease screening methods and proteases identified thereby
|
US8759087B2
(en)
|
2006-12-12 |
2014-06-24 |
Morpho Sys AG |
Internalization
|
WO2009024593A1
(en)
*
|
2007-08-21 |
2009-02-26 |
Morphosys Ag |
Improved methods for the formation of disulphide bonds
|
PL2199390T3
(pl)
|
2007-08-30 |
2017-06-30 |
Daiichi Sankyo Company, Limited |
Przeciwciało anty-epha2
|
CA3187687A1
(en)
|
2007-09-14 |
2009-03-19 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
NZ585551A
(en)
|
2007-11-26 |
2012-06-29 |
Bayer Schering Pharma Ag |
Anti-mesothelin antibodies and uses therefor
|
ATE555200T1
(de)
|
2008-02-05 |
2012-05-15 |
Medical Res Council |
Verfahren und zusammensetzungen
|
WO2009114815A1
(en)
|
2008-03-13 |
2009-09-17 |
Dyax Corp |
Libraries of genetic packages comprising novel hc cdr3 designs
|
EP2276511A2
(en)
|
2008-04-15 |
2011-01-26 |
Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
Compositions and methods for delivering inhibitory oligonucleotides
|
US10485879B2
(en)
|
2008-04-15 |
2019-11-26 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
|
PT2281078E
(pt)
|
2008-04-24 |
2015-02-05 |
Dyax Corp |
Bibliotecas de pacotes genéticos compreendendo desenhos de novas cdr1, cdr2, e cdr3 de hc e novas cdr1, cr2, e cdr3 de lc
|
DK2328616T3
(en)
|
2008-08-05 |
2015-07-20 |
Novartis Ag |
Compositions and Methods for Antibodies to Complement Protein C5
|
CA3073384A1
(en)
|
2008-09-05 |
2010-03-11 |
President And Fellows Of Harvard College |
Continuous directed evolution of proteins and nucleic acids
|
WO2010079189A1
(en)
|
2009-01-09 |
2010-07-15 |
Morphosys Ag |
Display vectors and methods and uses thereof
|
TWI480050B
(zh)
|
2009-02-10 |
2015-04-11 |
Daiichi Sankyo Co Ltd |
抗-mst1r抗體及其用途
|
EA201101572A1
(ru)
|
2009-04-27 |
2012-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
|
CA2993053A1
(en)
|
2009-04-27 |
2010-11-04 |
Novartis Ag |
Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
CA2759873A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Cytos Biotechnology Ag |
Influenza hemagglutinin compositions and uses thereof
|
PT2435568E
(pt)
|
2009-05-29 |
2014-10-08 |
Morphosys Ag |
Coleção de anticorpos sintéticos para o tratamento de doenças
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
JP2013504602A
(ja)
*
|
2009-09-14 |
2013-02-07 |
ダイアックス コーポレーション |
新しく設計したhccdr3を含む遺伝子パッケージライブラリー
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
ES2581571T3
(es)
*
|
2009-11-17 |
2016-09-06 |
Janssen Biotech, Inc. |
Presentación de proteínas diméricas de disulfuro vinculado en fagos filamentosos
|
US8450086B2
(en)
|
2009-11-17 |
2013-05-28 |
Centocor Ortho Biotech Inc. |
Bacterial membrane protein secretion
|
US9650432B2
(en)
|
2010-01-29 |
2017-05-16 |
Morphosys Ag |
Rodent combinatorial antibody libraries
|
SG185415A1
(en)
|
2010-05-06 |
2012-12-28 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
EP2566892B1
(en)
|
2010-05-06 |
2017-12-20 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
EP3336225B1
(en)
|
2010-07-16 |
2020-02-19 |
Adimab, LLC |
Antibody libraries
|
ES2620255T3
(es)
|
2010-08-20 |
2017-06-28 |
Novartis Ag |
Anticuerpos para el receptor del factor de crecimiento epidérmico 3 (HER3)
|
HUE041958T2
(hu)
|
2010-09-09 |
2019-06-28 |
Pfizer |
4-IBB-t kötõ molekulák
|
CN103237813A
(zh)
|
2010-10-05 |
2013-08-07 |
第一三共株式会社 |
靶向破骨细胞相关蛋白涎免凝集素-15的抗体
|
US8367586B2
(en)
|
2010-11-19 |
2013-02-05 |
Morphosys Ag |
Collection and methods for its use
|
US9394537B2
(en)
|
2010-12-22 |
2016-07-19 |
President And Fellows Of Harvard College |
Continuous directed evolution
|
JP2014526886A
(ja)
|
2011-07-15 |
2014-10-09 |
モルフォシス・アー・ゲー |
マクロファージ遊走阻止因子(mif)とd−ドーパクロームトートメラーゼ(d−dt)に交差反応性がある抗体
|
CA2852145C
(en)
|
2011-10-19 |
2021-01-12 |
Morphosys Ag |
Antagonists of il17c for the treatment of inflammatory disorders
|
CN108341873B
(zh)
|
2011-12-05 |
2022-03-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
JP2015500829A
(ja)
|
2011-12-05 |
2015-01-08 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体3(her3)のドメインiiに対するher3の抗体
|
CA2861137C
(en)
|
2012-02-03 |
2022-03-22 |
The Governors Of The University Of Alberta |
Method of quantifying peptide-derivative libraries using phage display
|
EP3508497A1
(en)
|
2012-05-24 |
2019-07-10 |
Mountgate Group Limited |
Compositions and methods related to prevention and treatment of rabies infection
|
US20150197579A1
(en)
|
2012-08-17 |
2015-07-16 |
Morphosys Ag |
Complex-specific antibodies and antibody fragments and its use
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
US9428577B2
(en)
|
2012-11-09 |
2016-08-30 |
Pfizer Inc. |
Platelet-derived growth factor B specific antibodies and compositions and uses thereof
|
CA2890483A1
(en)
|
2012-11-09 |
2014-05-15 |
Robert ARCH |
Platelet-derived growth factor b specific antibodies and compositions and uses thereof
|
US9873733B2
(en)
|
2012-12-20 |
2018-01-23 |
Morphosys Ag. |
Anti-staphylococcal antibodies
|
EP3611189A1
(en)
|
2013-03-14 |
2020-02-19 |
Novartis AG |
Antibodies against notch 3
|
MA38396B1
(fr)
|
2013-03-15 |
2019-05-31 |
Novartis Ag |
Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
|
SG11201507871XA
(en)
|
2013-04-12 |
2015-10-29 |
Morphosys Ag |
Antibodies targeting m-csf
|
US20160060347A1
(en)
|
2013-04-17 |
2016-03-03 |
Morphosys Ag |
Antibodies targeting specifically human cxcr2
|
RU2729463C2
(ru)
|
2013-12-20 |
2020-08-06 |
Фред Хатчинсон Кансэр Рисёч Сентер |
Меченые химерные эффекторные молекулы и их рецепторы
|
WO2015134121A2
(en)
|
2014-01-20 |
2015-09-11 |
President And Fellows Of Harvard College |
Negative selection and stringency modulation in continuous evolution systems
|
MX375919B
(es)
|
2014-03-14 |
2025-03-07 |
Immunocore Ltd |
Bibliotecas de tcr.
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
US10920208B2
(en)
|
2014-10-22 |
2021-02-16 |
President And Fellows Of Harvard College |
Evolution of proteases
|
CA2967188A1
(en)
|
2014-11-14 |
2016-05-19 |
Novartis Ag |
Antibody drug conjugates
|
JP2018518152A
(ja)
|
2015-03-27 |
2018-07-12 |
ユニバーシティ オブ サザン カリフォルニア |
充実性腫瘍を処置するためのlhrに指向されたcar t細胞治療
|
US11299729B2
(en)
|
2015-04-17 |
2022-04-12 |
President And Fellows Of Harvard College |
Vector-based mutagenesis system
|
WO2016176651A2
(en)
*
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
EP3095465A1
(en)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Combination of fgfr4-inhibitor and bile acid sequestrant
|
CA2987992A1
(en)
|
2015-06-04 |
2016-12-08 |
University Of Southern California |
Lym-1 and lym-2 targeted car cell immunotherapy
|
TN2017000417A1
(en)
|
2015-06-05 |
2019-01-16 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
WO2017015545A1
(en)
|
2015-07-22 |
2017-01-26 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
US11524983B2
(en)
|
2015-07-23 |
2022-12-13 |
President And Fellows Of Harvard College |
Evolution of Bt toxins
|
US10612011B2
(en)
|
2015-07-30 |
2020-04-07 |
President And Fellows Of Harvard College |
Evolution of TALENs
|
UY36889A
(es)
|
2015-09-09 |
2017-04-28 |
Novartis Ag |
Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
|
KR20180042433A
(ko)
|
2015-09-09 |
2018-04-25 |
노파르티스 아게 |
흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
|
GB201516272D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516269D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516270D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516274D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516265D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516277D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR libraries
|
GB201516275D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
EP3352784A4
(en)
|
2015-09-23 |
2019-06-26 |
Cytoimmune Therapeutics, LLC |
FLT3-FACED CAR CELLS FOR IMMUNOTHERAPY
|
JP7067793B2
(ja)
|
2015-10-23 |
2022-05-16 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
核酸塩基編集因子およびその使用
|
US11180546B2
(en)
|
2016-02-17 |
2021-11-23 |
Novartis Ag |
TGFbeta 2 antibodies
|
US20190048071A1
(en)
|
2016-02-19 |
2019-02-14 |
Morphosys Ag |
Antibodies for il-17c
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
EP3538552B1
(en)
|
2016-11-14 |
2023-09-13 |
MorphoSys AG |
Fab molecules with a rodent hinge region and a non-rodent ch1 region
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2019010164A1
(en)
|
2017-07-06 |
2019-01-10 |
President And Fellows Of Harvard College |
EVOLUTION OF ARNT SYNTHÉTASES
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
US12060553B2
(en)
|
2017-08-25 |
2024-08-13 |
President And Fellows Of Harvard College |
Evolution of BoNT peptidases
|
US11624130B2
(en)
|
2017-09-18 |
2023-04-11 |
President And Fellows Of Harvard College |
Continuous evolution for stabilized proteins
|
CN111587123A
(zh)
|
2017-11-09 |
2020-08-25 |
品通治疗有限公司 |
用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
|
JP2021503891A
(ja)
|
2017-11-22 |
2021-02-15 |
ノバルティス アーゲー |
抗第XI/XIa因子抗体に対する反転結合剤およびそれらの使用
|
WO2019193418A1
(en)
|
2018-04-05 |
2019-10-10 |
Bio-Rad Abd Serotec Gmbh |
Display systems for proteins of interest
|
EP3793596A1
(en)
|
2018-05-16 |
2021-03-24 |
MorphoSys AG |
Antibodies targeting glycoprotein vi
|
WO2019241649A1
(en)
|
2018-06-14 |
2019-12-19 |
President And Fellows Of Harvard College |
Evolution of cytidine deaminases
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
EP3938400A4
(en)
|
2019-03-11 |
2022-11-23 |
Memorial Sloan Kettering Cancer Center |
Cd22 antibodies and methods of using the same
|
SG11202108761YA
(en)
|
2019-03-14 |
2021-09-29 |
Morphosys Ag |
Antibodies targeting c5ar
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
IL299586A
(en)
|
2020-07-16 |
2023-03-01 |
Novartis Ag |
Anti-betacellulin antibodies, their fragments, and multispecific binding molecules
|
IL301276A
(en)
|
2020-09-24 |
2023-05-01 |
Morphosys Ag |
Novel human antibodies binding to human cd3 epsilon
|
TW202237135A
(zh)
|
2021-01-13 |
2022-10-01 |
紀念斯隆凱特琳癌症中心 |
抗體-吡咯并苯并二氮呯衍生物結合物
|
US20240115721A1
(en)
|
2021-01-13 |
2024-04-11 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
WO2023032955A1
(ja)
|
2021-08-31 |
2023-03-09 |
大正製薬株式会社 |
抗成長ホルモン抗体
|
KR20240158351A
(ko)
|
2022-03-22 |
2024-11-04 |
모르포시스 아게 |
Cd3에 특이적인 탈면역화 항체
|
GB202204159D0
(en)
|
2022-03-24 |
2022-05-11 |
Heptares Therapeutics Ltd |
Antibodies
|
WO2024236163A1
(en)
|
2023-05-17 |
2024-11-21 |
Morphosys Ag |
T cell receptor beta constant region 2 (trbc2) antibodies
|
WO2025003511A1
(en)
|
2023-06-30 |
2025-01-02 |
Morphosys Ag |
Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|